Inventory

The components of inventory are summarized as follows:



(In millions)	As of September 30, 2016		As of December 31, 2015
Raw materials	$	166.4	$	213.0
Work in process	712.0		577.6
Finished goods	171.1		143.0
Total inventory	$	1,049.5	$	933.6

Balance Sheet Classification:
Inventory	$	1,009.7	$	893.4
Investments and other assets	39.8		40.2
Total inventory	$	1,049.5	$	933.6

Inventory included in investments and other assets in our condensed consolidated balance sheets primarily consisted of work in process.

As of December 31, 2015, our inventory included $24.7 million associated with our ZINBRYTA program, $24.2 million associated with the FLIXABI program and $18.4 million associated with the BENEPALI program, which had been capitalized in advance of regulatory approval. The European Commission (EC) approved the marketing authorization applications for BENEPALI and FLIXABI, two anti-tumor necrosis factor (TNF) biosimilars, for marketing in the E.U. in January 2016 and May 2016, respectively. In addition, the U.S. Food and Drug Administration (FDA) approved ZINBRYTA for the treatment of relapsing forms of MS in the U.S. in May 2016, and the EC approved ZINBRYTA for the treatment of relapsing forms of MS in the E.U. in July 2016.